08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Aeroneb Go regulatory update

Aerogen said China's State Food and Drug Administration (SFDA) approved Aeroneb Pro and Aeroneb Go. Aeroneb Pro is a vibrating mesh nebulizer that creates aerosolized particles for drug delivery to the lungs. Aeroneb Go is...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Aerogen, Dance Pharma Inc deal

Aerogen and Dance partnered to develop Dance's inhaled insulin using Aerogen's OnQ aerosol technology. Under the deal, Dance received exclusive, worldwide rights to the technology, which delivers aerosolized drugs to the lungs, for use with...
07:00 , Aug 14, 2006 |  BC Week In Review  |  Company News

Biota, National Institutes of Health infectious news

BTA received the first $2.4 million installment of a four-year $8.5 million grant from NIH to develop Flunet, a class of long-acting dimeric neuraminidase inhibitors based on the molecular shape of zanamivir, to treat...
07:00 , Aug 7, 2006 |  BC Week In Review  |  Company News

InterMune management update

InterMune Inc. (ITMN), Brisbane, Calif.   Business: Musculoskeletal, Infectious, Pulmonary   Hired: John Hodgman as SVP and CFO, formerly president and CEO of Aerogen Inc.; he replaces Norman Halleen, who departed   ...
08:00 , Feb 6, 2006 |  BioCentury  |  Strategy

Waiting to inhale

For years, it was unclear to the outside world how Nektar Therapeutics would layer on the relatively low royalties it had to be getting from licensing its drug delivery technologies to create a substantial, profitable...
08:00 , Jan 9, 2006 |  BC Week In Review  |  Company News

Codexis management update

Codexis Inc., Redwood City, Calif.   Business: Supply/Service   Hired: Robert Breuil as SVP and CFO, formerly CFO and VP of corporate development at Aerogen Inc.   ...
07:00 , Oct 24, 2005 |  BC Week In Review  |  Company News

Aerogen, Nektar deal

NKTR completed its previously announced acquisition of AEGN for about $32 million in cash, or $0.75 per share (see BioCentury, Aug. 22). Aerogen Inc. (AEGN), Mountain View, Calif.   Nektar Therapeutics (NKTR), San Carlos, Calif.   Business:...
07:00 , Aug 22, 2005 |  BC Week In Review  |  Company News

Aerogen, Nektar deal

NKTR will acquire AEGN for about $32 million in cash, or $0.75 per share. Aquilo Partners advised AEGN in the deal, which is expected to close next quarter. AEGN develops and markets nebulizers and inhalers...
07:00 , Aug 22, 2005 |  BioCentury  |  Strategy

Filling an acute need

Having already made the leap from a royalty-based drug delivery model to become a company that is developing products of its own, Nektar Therapeutics is looking to branch out from its areas of expertise in...
00:49 , Aug 17, 2005 |  BC Extra  |  Financial News

Nektar raises $24 million

Drug delivery company NKTR raised $24 million through a private placement of 1.4 million shares with Mainfield Enterprises at $16.71, a 5% discount to Monday's close of $17.62. Mainfield also received a one-month option to...